xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05972577</url>
    </required_header>
    <id_info>
      <org_study_id>OSU-21010</org_study_id>
      <secondary_id>NCI-2021-10004</secondary_id>
      <nct_id>NCT05972577</nct_id>
    </id_info>
    <brief_title>Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study</brief_title>
    <official_title>Optimization of Older Adult Allogeneic Hematopoietic Cell Transplant Candidates to Improve Survival (OTIS)</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Ohio State University Comprehensive Cancer Center</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Ohio State University Comprehensive Cancer Center</source>
    <oversight_info>
      <has_dmc>Yes</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
      <is_us_export>No</is_us_export>
    </oversight_info>
    <brief_summary>
      <textblock>
        This clinical trial tests whether a geriatric optimization plan (GO!) works to improve&#xD;
        survival in patients over 60 with a hematologic malignancy or bone marrow failure syndrome&#xD;
        eligible for allogeneic hematopoietic cell transplant. GO! focuses on creating a tailored and&#xD;
        specific plan for each patient to make changes in their daily lives. These may include&#xD;
        changes to their diet, sleep, activity, medicines, or even referrals to other providers&#xD;
        depending on the patient's needs. Studying survival and quality of life in patients over 60&#xD;
        receiving an allogeneic hematopoietic cell transplant may help identify the effects of&#xD;
        treatment.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        PRIMARY OBJECTIVE:&#xD;
  &#xD;
        I. To demonstrate that geriatric assessment with management (GAM) intervention will lead to&#xD;
        improved physical functioning in allogeneic hematopoietic cell transplant (allo-HCT)-eligible&#xD;
        older adults as measured by improvement in 6-Minute Walk Test distance of at least 35 meters.&#xD;
  &#xD;
        SECONDARY OBJECTIVES:&#xD;
  &#xD;
        I. To demonstrate that GAM intervention will result in improvement in Short Physical&#xD;
        Performance Battery score by at least 1 point or score will remain &gt;= 10 for those with&#xD;
        baseline scores &gt;= 10.&#xD;
  &#xD;
        II. To demonstrate that GAM intervention will result in improvement in Mini Nutritional&#xD;
        Assessment score by at least 2 points or score will remain &gt;= 12 for those with baseline&#xD;
        scores &gt;= 12.&#xD;
  &#xD;
        III. To evaluate change in cognition and mental health as measured by Montreal Cognitive&#xD;
        Assessment, Personal Health Questionnaire-9, Generalized Anxiety Disorder-7, and Transplant&#xD;
        Evaluation Rating Scale score before and after GAM intervention.&#xD;
  &#xD;
        IV. To determine cumulative incidence rate for receipt of allo-HCT among study participants.&#xD;
  &#xD;
        V. To measure overall survival and non-relapse mortality among study participants.&#xD;
  &#xD;
        VI. To assess self-reported adherence to prescribed interventions. VII. To measure change in&#xD;
        patient-reported quality of life immediately following GAM intervention and up to one year&#xD;
        after completion of intervention.&#xD;
  &#xD;
        EXPLORATORY OBJECTIVES:&#xD;
  &#xD;
        I. To describe patterns of sleep and activity among study participants during intervention&#xD;
        period based on accelerometer data.&#xD;
  &#xD;
        II. To understand transplant physician rationale for not proceeding to allo-HCT for older&#xD;
        patients with eligible diagnoses.&#xD;
  &#xD;
        OUTLINE:&#xD;
  &#xD;
        Patients undergo personalized Geriatric Optimization (GO!) plan consisting of study visits&#xD;
        over 50 minutes at baseline and 6 months after first visit or at the time of hospital&#xD;
        admission for bone marrow transplant and over 25 minutes at 3 and 12 months after transplant.&#xD;
        Patients complete questionnaires once a month for up to 6 months and wear an accelerometer&#xD;
        for up to 6 months.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Active, not recruiting</overall_status>
    <start_date type="Actual">June 2, 2021</start_date>
    <completion_date type="Anticipated">December 31, 2024</completion_date>
    <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
    <phase>N/A</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>N/A</allocation>
      <intervention_model>Single Group Assignment</intervention_model>
      <primary_purpose>Supportive Care</primary_purpose>
      <masking>None (Open Label)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Change in 6-Minute Walk Test distance</measure>
      <time_frame>At 6 months before transplant, up to 12 months after transplant</time_frame>
      <description>Wilcoxon signed rank test or McNemar test will be used to assess the change over time in geriatric assessment tools.</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Change in Short Physical Performance Battery score</measure>
      <time_frame>At 6 months before transplant, up to 12 months after transplant</time_frame>
      <description>Wilcoxon signed rank test or McNemar test will be used to assess the change over time in geriatric assessment tools.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change in in Mini Nutritional Assessment score</measure>
      <time_frame>At 6 months before transplant, up to 12 months after transplant</time_frame>
      <description>Wilcoxon signed rank test or McNemar test will be used to assess the change over time in geriatric assessment tools.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change in cognitive and mental health</measure>
      <time_frame>At 6 months before transplant, up to 12 months after transplant</time_frame>
      <description>Measured by Montreal Cognitive Assessment Generalized Anxiety Disorder-7. Wilcoxon signed rank test or McNemar test will be used to assess the change over time in geriatric assessment tools.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change in cognitive and mental health</measure>
      <time_frame>At 6 months before transplant, up to 12 months after transplant</time_frame>
      <description>Measured by Personal Health Questionnaire-9. Wilcoxon signed rank test or McNemar test will be used to assess the change over time in geriatric assessment tools.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change in cognitive and mental health</measure>
      <time_frame>At 6 months before transplant, up to 12 months after transplant</time_frame>
      <description>Measured by Generalized Anxiety Disorder-7. Wilcoxon signed rank test or McNemar test will be used to assess the change over time in geriatric assessment tools.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change in cognitive and mental health</measure>
      <time_frame>At 6 months before transplant, up to 12 months after transplant</time_frame>
      <description>Measured by Transplant Evaluation Rating scale score. Wilcoxon signed rank test or McNemar test will be used to assess the change over time in geriatric assessment tools.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Proportion of sample achieving &quot;normal&quot; scores on geriatric assessment tools</measure>
      <time_frame>At 6 months before transplant, up to 12 months after transplant</time_frame>
      <description>McNemar test will be used to compare proportion of sample achieving normal scores on geriatric assessment tools.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Time to receipt of transplant</measure>
      <time_frame>Up to 1 year after treatment</time_frame>
      <description>Estimates of cumulative incidence of receipt of transplant with 95% confidence intervals will be provided for 100 days and one-year after end of treatment.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Overall survival</measure>
      <time_frame>Up to 12 months after transplant</time_frame>
      <description>Overall survival will be defined as the period from date of baseline assessment to death from any cause. Date of death will be confirmed by chart review. Will be estimated utilizing Kaplan-Meier method.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Non-relapse mortality</measure>
      <time_frame>Up to 12 months after transplant</time_frame>
      <description>Non-relapse mortality will be defined as the period from date of baseline assessment to death without evidence of relapsed primary hematologic disease. Relapse will be treated as competing risk. Documentation of date of relapse will be confirmed by chart review and collaboration with transplant physician if necessary. Estimates of cumulative incidence of non-relapse mortality with 95% confidence intervals will be provided for 100 days and one-year after end of treatment.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Adherence to prescribed geriatric optimization plan (GO!) prescription</measure>
      <time_frame>Up to 6 months after transplant</time_frame>
      <description>Will be assessed by self-report through monthly survey during intervention and at end-of-treatment assessment. Participants will be asked to estimate monthly frequency of completing all items in GO! prescription and this information will be collected through REDCap survey. Due to self-report nature of this item, no specific definition of adherence is offered beyond that which is asked of participants.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change in quality of life</measure>
      <time_frame>At 6 months before transplant, 3, and 6 month after transplant</time_frame>
      <description>Assessed with European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire and Elderly Cancer Patients Module. Wilcoxon signed rank test or McNemar test will be used to assess the change over time.</description>
    </secondary_outcome>
    <number_of_arms>1</number_of_arms>
    <enrollment type="Actual">30</enrollment>
    <condition>Acute Lymphoblastic Leukemia</condition>
    <condition>Acute Myeloid Leukemia</condition>
    <condition>Aplastic Anemia</condition>
    <condition>Chronic Lymphocytic Leukemia</condition>
    <condition>Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
    <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
    <condition>Hodgkin Lymphoma</condition>
    <condition>Myelodysplastic Syndrome</condition>
    <condition>Myelofibrosis</condition>
    <condition>Myeloproliferative Neoplasm</condition>
    <condition>Non-Hodgkin Lymphoma</condition>
    <condition>Plasma Cell Myeloma</condition>
    <arm_group>
      <arm_group_label>Supportive care (GO!)</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Patients undergo personalized GO! plan consisting of study visits over 50 minutes at baseline and 6 months after first visit or at the time of hospital admission for bone marrow transplant and over 25 minutes at 3 and 12 months after transplant. Patients complete questionnaires once a month for up to 6 months and wear an accelerometer for up to 6 months.</description>
    </arm_group>
    <intervention>
      <intervention_type>Other</intervention_type>
      <intervention_name>Health Promotion and Education</intervention_name>
      <description>Undergo GO!</description>
      <arm_group_label>Supportive care (GO!)</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Other</intervention_type>
      <intervention_name>Medical Device Usage and Evaluation</intervention_name>
      <description>Wear accelerometer</description>
      <arm_group_label>Supportive care (GO!)</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Other</intervention_type>
      <intervention_name>Quality-of-Life Assessment</intervention_name>
      <description>Complete quality of life assessments and diary entries</description>
      <arm_group_label>Supportive care (GO!)</arm_group_label>
      <other_name>Quality of Life Assessment</other_name>
    </intervention>
    <intervention>
      <intervention_type>Other</intervention_type>
      <intervention_name>Questionnaire Administration</intervention_name>
      <description>Complete questionnaires</description>
      <arm_group_label>Supportive care (GO!)</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Age &gt;= 60 years&#xD;
  &#xD;
            -  Diagnosed with hematologic malignancy or bone marrow failure syndrome eligible for&#xD;
               allogeneic hematopoietic cell transplantation. This includes acute myeloid leukemia,&#xD;
               acute lymphoblastic leukemia, myelodysplastic syndrome, myeloproliferative neoplasm,&#xD;
               myelofibrosis, chronic myeloid leukemia, chronic lymphocytic leukemia, non-Hodgkin&#xD;
               lymphoma, Hodgkin lymphoma, multiple myeloma, and aplastic anemia. Disease specific&#xD;
               eligibility for allo-HCT to be determined by treating physician&#xD;
  &#xD;
            -  Must be able to understand written and spoken English&#xD;
  &#xD;
            -  Must be willing to attend all study visits and comply with study procedures for the&#xD;
               entire length of the study&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Documented history of dementia&#xD;
  &#xD;
            -  No possibility of proceeding to allogeneic hematopoietic cell transplant within the&#xD;
               next 6 months as determined by treating physician&#xD;
  &#xD;
            -  Scheduled admission for allogeneic hematopoietic cell transplant within 30 days of&#xD;
               enrollment&#xD;
  &#xD;
            -  Inability or unwillingness to give written informed consent&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>60 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Sarah Wall, MD</last_name>
      <role>Principal Investigator</role>
      <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
    </overall_official>
    <location>
      <facility>
        <name>Ohio State University Comprehensive Cancer Center</name>
        <address>
          <city>Columbus</city>
          <state>Ohio</state>
          <zip>43210</zip>
          <country>United States</country>
        </address>
      </facility>
    </location>
    <location_countries>
      <country>United States</country>
    </location_countries>
    <link>
      <url>http://cancer.osu.edu</url>
      <description>The Jamesline</description>
    </link>
    <verification_date>July 2023</verification_date>
    <study_first_submitted>July 13, 2022</study_first_submitted>
    <study_first_submitted_qc>July 24, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 2, 2023</study_first_posted>
    <last_update_submitted>July 24, 2023</last_update_submitted>
    <last_update_submitted_qc>July 24, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 2, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Principal Investigator</responsible_party_type>
      <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
      <investigator_full_name>Sarah Wall</investigator_full_name>
      <investigator_title>Principal Investigator</investigator_title>
    </responsible_party>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Lymphoma</mesh_term>
      <mesh_term>Leukemia</mesh_term>
      <mesh_term>Neoplasms</mesh_term>
      <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
      <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
      <mesh_term>Leukemia, Myeloid</mesh_term>
      <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
      <mesh_term>Multiple Myeloma</mesh_term>
      <mesh_term>Myelodysplastic Syndromes</mesh_term>
      <mesh_term>Myeloproliferative Disorders</mesh_term>
      <mesh_term>Anemia, Aplastic</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05972577
  org study id: OSU-21010
  secondary id: NCI-2021-10004
  nct id: NCT05972577
  lead sponsor: 
  has dmc: Yes
  is fda regulated drug: No
  is fda regulated device: No
  is us export: No
  This clinical trial tests whether a geriatric optimization plan (GO!) works to improve
        survival in patients over 60 with a hematologic malignancy or bone marrow failure syndrome
        eligible for allogeneic hematopoietic cell transplant. GO! focuses on creating a tailored and
        specific plan for each patient to make changes in their daily lives. These may include
        changes to their diet, sleep, activity, medicines, or even referrals to other providers
        depending on the patient's needs. Studying survival and quality of life in patients over 60
        receiving an allogeneic hematopoietic cell transplant may help identify the effects of
        treatment.
  PRIMARY OBJECTIVE:
  
        I. To demonstrate that geriatric assessment with management (GAM) intervention will lead to
        improved physical functioning in allogeneic hematopoietic cell transplant (allo-HCT)-eligible
        older adults as measured by improvement in 6-Minute Walk Test distance of at least 35 meters.
  
        SECONDARY OBJECTIVES:
  
        I. To demonstrate that GAM intervention will result in improvement in Short Physical
        Performance Battery score by at least 1 point or score will remain >= 10 for those with
        baseline scores >= 10.
  
        II. To demonstrate that GAM intervention will result in improvement in Mini Nutritional
        Assessment score by at least 2 points or score will remain >= 12 for those with baseline
        scores >= 12.
  
        III. To evaluate change in cognition and mental health as measured by Montreal Cognitive
        Assessment, Personal Health Questionnaire-9, Generalized Anxiety Disorder-7, and Transplant
        Evaluation Rating Scale score before and after GAM intervention.
  
        IV. To determine cumulative incidence rate for receipt of allo-HCT among study participants.
  
        V. To measure overall survival and non-relapse mortality among study participants.
  
        VI. To assess self-reported adherence to prescribed interventions. VII. To measure change in
        patient-reported quality of life immediately following GAM intervention and up to one year
        after completion of intervention.
  
        EXPLORATORY OBJECTIVES:
  
        I. To describe patterns of sleep and activity among study participants during intervention
        period based on accelerometer data.
  
        II. To understand transplant physician rationale for not proceeding to allo-HCT for older
        patients with eligible diagnoses.
  
        OUTLINE:
  
        Patients undergo personalized Geriatric Optimization (GO!) plan consisting of study visits
        over 50 minutes at baseline and 6 months after first visit or at the time of hospital
        admission for bone marrow transplant and over 25 minutes at 3 and 12 months after transplant.
        Patients complete questionnaires once a month for up to 6 months and wear an accelerometer
        for up to 6 months.
  allocation: N/A
  intervention model: Single Group Assignment
  primary purpose: Supportive Care
  masking: None (Open Label)
  measure: Change in 6-Minute Walk Test distance
  time frame: At 6 months before transplant, up to 12 months after transplant
  description: Wilcoxon signed rank test or McNemar test will be used to assess the change over time in geriatric assessment tools.
  measure: Change in Short Physical Performance Battery score
  time frame: At 6 months before transplant, up to 12 months after transplant
  description: Wilcoxon signed rank test or McNemar test will be used to assess the change over time in geriatric assessment tools.
  measure: Change in in Mini Nutritional Assessment score
  time frame: At 6 months before transplant, up to 12 months after transplant
  description: Wilcoxon signed rank test or McNemar test will be used to assess the change over time in geriatric assessment tools.
  measure: Change in cognitive and mental health
  time frame: At 6 months before transplant, up to 12 months after transplant
  description: Measured by Montreal Cognitive Assessment Generalized Anxiety Disorder-7. Wilcoxon signed rank test or McNemar test will be used to assess the change over time in geriatric assessment tools.
  measure: Change in cognitive and mental health
  time frame: At 6 months before transplant, up to 12 months after transplant
  description: Measured by Personal Health Questionnaire-9. Wilcoxon signed rank test or McNemar test will be used to assess the change over time in geriatric assessment tools.
  measure: Change in cognitive and mental health
  time frame: At 6 months before transplant, up to 12 months after transplant
  description: Measured by Generalized Anxiety Disorder-7. Wilcoxon signed rank test or McNemar test will be used to assess the change over time in geriatric assessment tools.
  measure: Change in cognitive and mental health
  time frame: At 6 months before transplant, up to 12 months after transplant
  description: Measured by Transplant Evaluation Rating scale score. Wilcoxon signed rank test or McNemar test will be used to assess the change over time in geriatric assessment tools.
  measure: Proportion of sample achieving "normal" scores on geriatric assessment tools
  time frame: At 6 months before transplant, up to 12 months after transplant
  description: McNemar test will be used to compare proportion of sample achieving normal scores on geriatric assessment tools.
  measure: Time to receipt of transplant
  time frame: Up to 1 year after treatment
  description: Estimates of cumulative incidence of receipt of transplant with 95% confidence intervals will be provided for 100 days and one-year after end of treatment.
  measure: Overall survival
  time frame: Up to 12 months after transplant
  description: Overall survival will be defined as the period from date of baseline assessment to death from any cause. Date of death will be confirmed by chart review. Will be estimated utilizing Kaplan-Meier method.
  measure: Non-relapse mortality
  time frame: Up to 12 months after transplant
  description: Non-relapse mortality will be defined as the period from date of baseline assessment to death without evidence of relapsed primary hematologic disease. Relapse will be treated as competing risk. Documentation of date of relapse will be confirmed by chart review and collaboration with transplant physician if necessary. Estimates of cumulative incidence of non-relapse mortality with 95% confidence intervals will be provided for 100 days and one-year after end of treatment.
  measure: Adherence to prescribed geriatric optimization plan (GO!) prescription
  time frame: Up to 6 months after transplant
  description: Will be assessed by self-report through monthly survey during intervention and at end-of-treatment assessment. Participants will be asked to estimate monthly frequency of completing all items in GO! prescription and this information will be collected through REDCap survey. Due to self-report nature of this item, no specific definition of adherence is offered beyond that which is asked of participants.
  measure: Change in quality of life
  time frame: At 6 months before transplant, 3, and 6 month after transplant
  description: Assessed with European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire and Elderly Cancer Patients Module. Wilcoxon signed rank test or McNemar test will be used to assess the change over time.
  arm group label: Supportive care (GO!)
  arm group type: Experimental
  description: Patients undergo personalized GO! plan consisting of study visits over 50 minutes at baseline and 6 months after first visit or at the time of hospital admission for bone marrow transplant and over 25 minutes at 3 and 12 months after transplant. Patients complete questionnaires once a month for up to 6 months and wear an accelerometer for up to 6 months.
  intervention type: Other
  intervention name: Health Promotion and Education
  description: Undergo GO!
  arm group label: Supportive care (GO!)
  intervention type: Other
  intervention name: Medical Device Usage and Evaluation
  description: Wear accelerometer
  arm group label: Supportive care (GO!)
  intervention type: Other
  intervention name: Quality-of-Life Assessment
  description: Complete quality of life assessments and diary entries
  arm group label: Supportive care (GO!)
  other name: Quality of Life Assessment
  intervention type: Other
  intervention name: Questionnaire Administration
  description: Complete questionnaires
  arm group label: Supportive care (GO!)
  criteria: 
  gender: All
  minimum age: 60 Years
  maximum age: N/A
  healthy volunteers: No
  last name: Sarah Wall, MD
  role: Principal Investigator
  affiliation: Ohio State University Comprehensive Cancer Center
  facility: 
  country: United States
  url: http://cancer.osu.edu
  description: The Jamesline
  responsible party type: Principal Investigator
  investigator affiliation: Ohio State University Comprehensive Cancer Center
  investigator full name: Sarah Wall
  investigator title: Principal Investigator
  mesh term: Lymphoma
  mesh term: Leukemia
  mesh term: Neoplasms
  mesh term: Precursor Cell Lymphoblastic Leukemia-Lymphoma
  mesh term: Leukemia, Lymphocytic, Chronic, B-Cell
  mesh term: Leukemia, Myeloid
  mesh term: Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  mesh term: Multiple Myeloma
  mesh term: Myelodysplastic Syndromes
  mesh term: Myeloproliferative Disorders
  mesh term: Anemia, Aplastic
  sharing ipd: No